SCHEMBL904487

SCHEMBL904487

CCC(C(=O)O)C(=O)c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.51
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
GSK3B P49841 2/20 0.47
EPHX2 P34913 1/20 0.46
PPARG P37231 1/20 0.46
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
POLB P06746 2/20 0.45
CES2 O00748 3/20 0.45
CES1 P23141 3/20 0.45
SRD5A2 P31213 1/20 0.44
MDM2 Q00987 2/20 0.43
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP12 P39900 1/20 0.43
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11033678 0.85 HTT (0.49) HTTALOX15TSHRGSK3BCYP2C9
SCHEMBL9352397 0.85 MMP2 (0.48) HTTALOX15TSHRGSK3BPPARG
SCHEMBL27807280 0.84 HTT (0.45) HTTALOX15TSHRGSK3BEPHX2
SCHEMBL16553310 0.82 LMNA (0.59) HTTALOX15TSHRCYP2C9CYP2C19
SCHEMBL2289091 0.82 ALDH1A1 (0.50) HTTGSK3BPOLBCES2CES1
SCHEMBL9356173 0.82 MMP2 (0.51) HTTALOX15TSHRGSK3BPPARG
SCHEMBL442090 0.82 MDM2 (0.59) HTTTSHRGSK3BCES2CES1
SCHEMBL342966 0.81 GSK3B (0.48) HTTGSK3BPOLBCES2CES1
SCHEMBL5509922 0.81 CYP2C9 (0.53) ALOX15TSHRGSK3BCYP2C9CYP2C19
SCHEMBL7229416 0.81 TPMT (0.48) HTTMDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238633-B2 Methods for treating diabetic complications with carbamoyloxy arylalkanoyl arylpiperazine compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-01-19 US disclosed
US-8901116-B2 Method for treating pain, anxiety or depression using carbamoyloxy alkanoyl piperazine compound SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-12-02 US disclosed
US-20140243352-A1 METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-08-28 US disclosed
US-20140088095-A1 METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-03-27 US disclosed
US-8648083-B2 Method of treating diabetic hyperlipidemia or hyperlipidemia with carbamoyloxy arylalkanoyl arylpiperazine compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-02-11 US disclosed
US-8541409-B2 Carbamoyloxy arylalkanoyl arylpiperazine analgesics SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-09-24 US disclosed
US-20130131081-A1 PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-05-23 US disclosed
EP-2590650-A2 PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND SK Biopharmaceuticals Co., Ltd. (KR) 2013-05-15 EP disclosed
WO-2012005536-A2 PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND SK BIOPHARMACEUTICALS CO., LTD. (KR) 2012-01-12 WO disclosed
EP-2155736-B1 NOVEL CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO LTD (KR) 2011-12-21 EP disclosed
US-7101873-B2 Pyrimidinedione derivatives BEXEL PHARMACEUTICALS INC. (US) 2006-09-05 US disclosed
US-20060194799-A1 Novel pyrimidinedione derivatives BEXEL PHARMACEUTICALS INC. (US) 2006-08-31 US disclosed
EP-0742211-B1 PYRIDAZINONE DERIVATIVES NISSAN CHEMICAL IND LTD (JP) 2000-05-10 EP disclosed
US-5856327-A INHIBITING PLATELET AGGREGATION NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1999-01-05 US disclosed
US-5750523-A INHIBITING PLATELET AGGREGATION NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1998-05-12 US disclosed
EP-0742211-A1 PYRIDAZINONE DERIVATIVE NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1996-11-13 EP disclosed
EP-0412933-B1 Coating compositions CIBA GEIGY AG (CH) 1994-09-14 EP disclosed
US-5183842-A Mixture of ketoacid and amine with film-forming binder, curing CIBA-GEIGY CORPORATION (US) 1993-02-02 US disclosed
US-5128396-A Corrosion inhibiting primers on metallic substrates CIBA-GEIGY CORPORATION (US) 1992-07-07 US disclosed
EP-0412933-A1 Coating compositions CIBA-GEIGY AG (CH) 1991-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131081-A1 PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND LIPG, CETP, GPR119 HTT 1164/4885ALOX15 46/4885TSHR 3750/4885
US-20060194799-A1 Novel pyrimidinedione derivatives TYMS, TYMP, DPYD HTT 3239/4885ALOX15 1142/4885TSHR 4039/4885
US-20140088095-A1 METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND HTR5A, OPRL1, HDAC3 HTT 665/4885ALOX15 143/4885TSHR 2865/4885
US-20140243352-A1 METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS LIPG, DPP7, IAPP HTT 1248/4885ALOX15 15/4885TSHR 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.